Skip to content

Breast Cancer Health Center

Breast Cancer Treatment: Weighing the Hormonal Options

Tamoxifen has been the standard in hormonal breast cancer treatment for decades. But newer treatments are challenging tamoxifen's superiority.
Font Size
A
A
A

WebMD Feature

To Kathryn Anderson, the hormonal treatment tamoxifen offered a new lease on life. A survivor of breast cancer, she had been through two surgeries, radiation therapy, and chemotherapy when her doctors put her on tamoxifen.

Anderson is not alone. In the 25-plus years since tamoxifen became a mainstay of breast cancer therapy, the pill has saved thousands of lives. But now, newer hormonal agents known as aromatase inhibitors are contesting the superiority of tamoxifen and competing for attention.

Recommended Related to Breast Cancer

Women’s Cancer Q&A: Advances in Care

How far have we come in women’s cancer? Keeping up with the latest treatment trends and studies about cancer of the breast, ovary, uterus, and cervix can be daunting. New studies come out seemingly every week with hot-off-the-press -- and often contradictory -- results. Mammograms? They’re either the key to prevention or misleading at best. And what’s the final word on hormone replacement therapy? Does it prevent or cause cancer? Experts have even recently challenged the value of sticking to...

Read the Women’s Cancer Q&A: Advances in Care article > >

One of the biggest concerns with tamoxifen is that it stops working after five years, doctors say. Yet one-third of cancers that recur come back between five and 10 years later.

Anderson says that after her five years of tamoxifen therapy ended she always feared a recurrence, feeling that her safety net had gone away.

Until now. A study published in 2004 in The New England Journal of Medicine showed that taking the aromatase inhibitor Aromasin after two to three years of tamoxifen reduced breast cancer recurrence by 32%.

And in 2003, another study in the same journal showed that women could cut their risk of recurrence by nearly half by taking the aromatase inhibitor Femara after they completed about five years on tamoxifen.

And another recent study showed that postmenopausal women who switch to another aromatase inhibitor, Arimidex, after two or three years of tamoxifen therapy had fewer recurrences of cancer than those who continued to take tamoxifen for the full recommended five years.

Aromasin Helps Prevent Cancer Recurrence

The Aromasin study, performed by R. Charles Coombes, MD, PhD, showed that when postmenopausal women took Aromasin for two to three years following two to three years of treatment with tamoxifen, the risk of breast cancer recurrence dropped by 32% compared with women who continued to take tamoxifen.

It's a revolutionary finding, says Paul E. Goss, MD, PhD, director of breast cancer prevention at Toronto's Princess Margaret Hospital and professor of medicine at the University of Toronto. Goss was lead researcher on the Femara study that showed it cut breast cancer recurrence nearly in half after five years of tamoxifen.

1 | 2 | 3 | 4

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
 
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW